Ichor Therapeutics, Inc. (www.ichortherapeutics.com) is a pre-clinical biotechnology company focused on age-related disease, broadly. The company has two active programs, a lysoSENS inspired enzyme therapy for Stargardt's macular degeneration and age-related macular degeneration, and an oncology program based on C60oo described by Baati et al. Ichor also conducts limited contract research work for 3rd parties, mostly pertaining to lifespan studies.
The company is located 10 minutes south of Syracuse, New York. Its facility is a stand-alone 8,400 sq foot office/wet lab space and includes a 2,500 sq ft vivarium suitable for SCID work. Company infrastructure spans cell biology (mammalian cell culture incubators, flow hoods, flow cytometers, molecular biology equipment, bioreactors, shaker incubators, fluorescence microscopes, abs/lum/flu plate readers, etc.), analytical chemistry (HPLC systems, FTIR, UV/VIS spec, nearby access to LC/MS-MS), automation (several liquid handling robots) husbandry (7,000 mouse capacity, surgical expertise, chem/CBC/etc. panels) and more. The laboratory is currently adopting GLP compliance standards.
Ichor has an open application process for prospective interns and job applicants. For entrepreneurs, Ichor offers private office and shared access to its research infrastructure (deals negotiated on a case-by-case basis, equity only deals permitted for some applicants).
General inquiries:
Stephanie Martens
info@ichortherapeutics.com
PI:
Kelsey Moody
kelsey.moody@ichortherapeutics.com
